July 31, 2017
On World Lung Cancer Day, 1st August 2017, Oncimmune celebrate, commemorate & support all those affected by lung cancer.
World Lung Cancer day, now in its 6th year, was first started by Betsy Thompson, founder of the Lung Cancer Survivors Foundation. World Lung Cancer Day was originally called Lung Cancer Survivor Day and was designed to bring survivors and sufferers together, to give them a united voice to inform and promote all causes and symptoms of lung cancer. World Lung Cancer Day isn’t a day promoting anti-smoking, it is a day dedicated to promoting awareness of lung cancer and all of its causes. Lung cancer was often thought of as the smoking disease, but not all cases of lung cancer are attributed to smoking. Other risk factors such as genetics, a history of cancer and the environment (eg: radon, asbestos, and uranium) also need to be considered.
Since its inception, the day has grown in recognition and is now being advocated by many key organisations who are members of the Forum of International Respiratory Societies (FIRS) including the American College of Chest Physicians (CHEST), American Thoracic Society (ATS) and the European Respiratory Society (ERS).
2015 saw FIRS create a campaign called Honour, Unite, Inspire. This was to enable physicians, patients and caregivers to have access to free downloadable materials.
2017 needs World Lung Cancer Day to continue to celebrate, commemorate and support the people affected by lung cancer. Lung cancer is still the biggest killer compared to all the other cancers, so make the day a priority – wear a white or translucent ribbon, support local events or check out The Lung Cancer Survivors Foundation Page for more ideas.
Oncimmune has developed and commercialised the EarlyCDT®–Lung, a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer. EarlyCDT®–Lung has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.